Dr. Mirakhur is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
700 Lawn Ave
Sellersville, PA 18960Phone+1 215-453-4000
Education & Training
Temple University Hospital/Chestnut Hill HospitalResidency, Family Medicine, 2001 - 2004
Lewis Katz School of Medicine at Temple UniversityClass of 2001
Certifications & Licensure
CA State Medical License 2019 - 2025
NJ State Medical License 2016 - 2023
PA State Medical License 2001 - 2021
American Board of Family Medicine Family Medicine
Clinical Trials
- Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors Start of enrollment: 2017 Apr 04
Publications & Presentations
PubMed
- 7 citationsNovel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent...Clarisse Dromain, Arturo Loaiza-Bonilla, Beloo Mirakhur, Thomas J. R. Beveridge, Antonio Tito Fojo
The Oncologist. 2021-04-01 - 17 citationsLiposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.Teresa Macarulla, Jean-Frédéric Blanc, Andrea Wang-Gillam, Li-Tzong Chen, Jens T. Siveke
Journal of Geriatric Oncology. 2019-03-04 - 33 citationsEconomic burden associated with adverse events in patients with metastatic melanoma.Bhakti Arondekar, Suellen M. Curkendall, Matthew J. Monberg, Beloo Mirakhur, Alan Oglesby
Journal of Managed Care & Specialty Pharmacy. 2015-10-16
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
